Klotho Neurosciences ALS gene therapy KLTO-202 is advancing through a critical phase of manufacturing and process development, positioning the company for early-stage clinical trials by Q3 2026. This significant milestone reflects Klotho Neurosciences, Inc. (NASDAQ: KLTO)'s ongoing commitment to tackling amyotrophic lateral sclerosis (ALS),...